Filing Summary
Identity note: The supplied filing is BioSante Pharmaceuticals, Inc.’s Form 10-Q, not ANI Pharmaceuticals, Inc.’s. It covers the quarter and nine months ended September 30, 2011; the interim financial statements are unaudited.
Business context
BioSante was a development-stage specialty pharmaceutical company focused on female sexual health and oncology. Its lead candidate, LibiGel, was in Phase III development for hypoactive sexual desire disorder. Elestrin was FDA-approved and marketed in the U.S. by a licensee; Bio-T-Gel’s NDA was pending, and the company also had earlier-stage contraceptive and cancer-vaccine programs.
Financial performance and position
| Metric | Q3 2011 | Nine months 2011 | Comparison |
|---|---|---|---|
| Revenue | $182,784 | $320,787 | Q3 2010: $51,331; nine-month 2010: $2.33 million |
| Research and development | $11.50 million | $37.48 million | Up 18.4% and 34.8%, respectively |
| General and administrative | $1.68 million | $5.26 million | Up 9.2% and 8.6%, respectively |
| Net loss | $12.73 million | $44.96 million | Prior-year periods: $11.59 million and $32.92 million |
| Loss per share | $0.12 | $0.48 | Prior-year periods: $0.16 and $0.51 |
For the nine months, operating cash use was $36.94 million, investing cash use was $0.65 million, and financing provided $69.04 million. Cash and cash equivalents were $69.60 million at September 30, up from $38.16 million at year-end 2010. Total assets were $74.89 million, current liabilities $11.50 million, total liabilities $30.74 million, and stockholders’ equity $44.15 million. The company reported an accumulated deficit of $210.59 million.
Debt consisted principally of $20.782 million principal of 3.125% convertible notes due May 2013, carried at fair value of $19.24 million at quarter-end. The $1.234 million principal of notes due November 1, 2011 was repaid in full after quarter-end, along with accrued interest. The filing does not present meaningful operating margins; revenue was small relative to research and development and administrative expenses.
Material changes and unusual items
- Nine-month revenue fell 86.2%, primarily because 2010 included approximately $2.3 million of Elestrin-related payments recognized following a license amendment. 2011 revenue included a $100,000 upfront fee from the Hussman Foundation and Elestrin royalties.
- Higher LibiGel Phase III costs drove increased research and development spending and contributed to the larger net loss.
- The company raised net proceeds of $23.9 million in a March registered direct offering and approximately $45.1 million in an August public offering. The resulting share issuance increased the weighted-average share count substantially.
- A $367,274 write-down of equipment no longer used in clinical development was included in research and development expense.
- Convertible-note fair-value movements affected reported results: a $1.9 million expense for the nine-month period, but a $463,000 liability decrease/expense benefit in Q3.
Outlook, risks and contingencies
- Management expected September 30 cash to fund liquidity needs for at least 18 months, while warning that estimates could prove incorrect. It expected continuing substantial losses for at least 18–24 months.
- Expected LibiGel research and development spending was $3–4 million monthly through year-end 2011, declining to $2–3 million monthly thereafter. These are estimates, not guarantees.
- Top-line results from the two LibiGel efficacy trials were expected in December 2011. The safety study had enrolled 3,656 participants; primary safety analysis was targeted for Q3 2012 and NDA submission for Q4 2012. The independent monitoring committee recommended continuing the study without changes.
- Bio-T-Gel’s FDA action date had been extended to February 14, 2012 after an additional-information request. Abbott Laboratories’ patent-infringement complaint against Teva could delay approval or launch and affect potential royalties.
- The company had no credit facility. Its Kingsbridge equity facility, available subject to conditions and at a discount, expired in December 2011; BioSante said it did not intend to use or renew it. It was evaluating licensing, collaborations, asset transactions and other strategic alternatives, including a possible sale.
- Key risks include clinical and regulatory outcomes, ability to obtain financing, reliance on licensees and licensors, third-party manufacturing and clinical support, competition, and market acceptance. The company reported no material change to previously disclosed risk factors.
Investor verification priorities
- Confirm the filing belongs to BioSante Pharmaceuticals, Inc.; the request metadata names ANI Pharmaceuticals, Inc.
- Check subsequent LibiGel efficacy and safety-study results and whether the stated NDA timing changed.
- Track cash burn against the 18-month liquidity estimate and assess whether additional financing or a strategic transaction became necessary.
- Verify the repayment of the November 2011 notes and monitor the 2013 convertible notes and potential dilution.
- Follow the Bio-T-Gel FDA review and Abbott-Teva patent litigation, including effects on approval timing and royalties.